FSLLRY-NH2 Improves Neurological Outcome After Cardiac Arrest in Rats

Umut OCAK¹,²,*, Pinar ESER OCAK²,³, Lei HUANG²,⁺⁺, John H. ZHANG²,⁺⁺,+++  
¹University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Department of Emergency Medicine, Bursa, Turkey  
²Loma Linda University School of Medicine, Department of Physiology and Pharmacology, Loma Linda, California, USA  
³Uludag University, School of Medicine, Department of Neurosurgery, Bursa, Turkey  

Corresponding author: John H. ZHANG  johnzhang3910@yahoo.com

ABSTRACT

AIM: To evaluate the effect of FSLLRY-NH2, a protease-activated receptor 2 (PAR2) inhibitor, on neurocognitive impairment and hippocampal neuronal degeneration in the setting of asphyxial cardiac arrest (ACA)-induced global cerebral ischemia (GCI) in rats.  

MATERIAL and METHODS: A total of 43 Sprague-Dawley male rats were used. Shams and rats resuscitated from 9 minutes of ACA were randomized to two separate experiments including time course and short-term neurological outcomes. FSLLRY-NH2 (50 microgram [μg] per rat) was administered intranasally at 1 hour postresuscitation. Neurological function and hippocampal neuronal degeneration were evaluated after ACA.  

RESULTS: Significant neurological function decline and hippocampal neuron degeneration were observed in ACA animals as compared with the shams. Treatment with FSLLRY-NH2 significantly improved neurological outcome and reduced the number of degenerating hippocampal neurons after ACA.  

CONCLUSION: Targeting PAR2 may be a novel therapeutic approach in the management of neurological dysfunction after cardiac arrest-associated ischemic injury.  

KEYWORDS: Cardiac arrest, cognitive, global cerebral ischemia, PAR2

INTRODUCTION

Cardiac arrest (CA) is associated with significant mortality and severe neurofunctional impairment (3,7). In cases of successful resuscitation, return of spontaneous circulation (ROSC) causes ischemia or reperfusion injury in the globally ischemic brain. As a result, global cerebral ischemia (GCI), which occurs during the arrest period and subsequent reperfusion (27), causes irreversible brain damage (17), and results in unfavorable neurological outcomes in CA survivors (14).  

Given the susceptibility of particular brain regions to ischemia, such as the cornu ammonis 1 (CA1) region of the hippocampus (16), cognitive dysfunction is an important consequence of CA-induced GCI (11,34,37). Among many other injury mechanisms, neuroinflammation has long been implicated in neurodegeneration and cognitive disability (5,23,26) as well as GCI-associated neurological dysfunction (4,21). Despite particular interest of a large number of research studies in CA-associated neurological impairment, including cognitive dysfunction, effective strategies are yet to be elucidated.  

Protease-activated receptor 2 (PAR2) is a member of the PAR family that is widely expressed in the resident cells of the central nervous system (20). Emerging evidence has pointed out that activation of PAR2 is related to neuroinflammation and neurodegeneration (12,18,35). Moreover, data obtained from both in vivo and in vitro studies underlined augmented expression of PAR2 in the brain after ischemic injury (25,36). Based on this background and given the potential involvement of neuroinflammation in CA-associated cognitive
decline (4), we hypothesized that inhibition of PAR2 could attenuate neurological impairment and hippocampal neuronal degeneration in the setting of asphyxial CA (ACA)-induced GCI.

## MATERIAL and METHODS

### Animals and Rat Models of ACA

All experimental procedures performed in the current study were approved by the Institutional Animal Care and Use Committee at Loma Linda University, Loma Linda, California, USA. All experiments conducted were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The results were reported according to the ARRIVE guidelines.

A total of 43 adult male Sprague-Dawley rats (450–500 g; Envigo, Indiana, USA) were used for this study. The animals were housed in a humidity- and temperature-controlled facility with 12 hours light and dark cycle and ad libitum food and water access.

The animals were randomly divided into sham (n=10), and ACA groups (n=33). Rats were anesthetized deeply with pentobarbital (intraperitoneal, 45 mg/kg; Virbac AH, Inc., Fort Worth, Texas, USA). First, endotracheal intubation using a 14-gauge plastic catheter under laryngoscopy was performed to the animals. Next, the left femoral artery and vein were exposed through a 1-centimeter skin incision along the left groin followed by blunt dissection of the surrounding connective tissue. Then, a polyethylene (PE) 50 catheter (Becton Dickinson, Franklin Lakes, New Jersey, USA) was inserted in the femoral artery and connected to a pressure transducer. Another PE 50 catheter was inserted in the femoral vein for drug administration. A rectal probe (Model BAT-12, Physitemp Instrument Inc, Clifton, New Jersey, USA) was inserted to monitor rectal body temperature during the procedure. Electrocardiogram (Lead II) was recorded continuously. The rats were mechanically ventilated (respiratory frequency, 100 beats per minute; tidal volume, 0.55 mL/100 g; FiO₂, 21%) for 15 minutes before the induction of ACA. ACA was induced by chemical neuromuscular blockade with intravenous vecuronium (2 mg/kg; Mylan Institutional LLC., Rockford, Illinois, USA). The ventilator was disconnected, and the intubation tube was obstructed. After 9 minutes of untreated asphyxia, resuscitation was initiated by unclamping the tracheal tube, administering epinephrine (7.5 μg/kg; International Medication System, LLC., South El Monte, California, USA) and sodium bicarbonate (1 mEq/kg; Hospira, Lake Forest, Illinois, USA), and applying precordial compressions with a pneumatically driven mechanical chest compressor as well as mechanical ventilation with 100% oxygen at a ratio of 2:1. Mean arterial pressure of >60 mmHg and return of sinus rhythm for 5 minutes were defined as successful resuscitation and ROSC.

The animals were excluded from the study if ROSC was achieved after 5 minutes of resuscitation or if ROSC was not achieved at all. After ROSC, mechanical ventilation was continued for 30 minutes with 100% oxygen and was gradually reduced to 21% every 10 minutes within 1 hour. The animals were weaned from the ventilator; endotracheal tube and all catheters were removed 1 hour after resuscitation. The wound was sutured, and the animals were allowed to recover. Their body temperature was maintained at 36.5 °C ± 0.5 °C using a heating lamp. The sham group underwent similar surgical procedures and baseline ventilation without inducing ACA. Electrocardiogram, end-tidal carbon dioxide, and arterial blood pressure were continuously recorded during the whole procedure from 15 minutes before asphyxia induction until 1 hour after ROSC on a PC-based data-acquisition system supported by WINDAQ software (DATAQ, Akron, Ohio, USA).

### Experimental Design

Two main experiments including time course or cellular colocalization of PAR2 and short-term (7 day) outcome of PAR2 inhibitor treatment were performed. The number and distribution of animals per experimental group are presented in Table I.

#### Experiment 1 (Time course study and cellular colocalization of PAR2)

The temporal expression of endogenous brain PAR2 was evaluated through Western blot at 6, 12, 24, and 72 hours after ACA (n=4 per group). Cellular colocalization of PAR2 with microglia marker calcium-binding adaptor molecule 1 (Iba1), astrocyte marker glial fibrillary acidic protein (GFAP), or neuron marker (NeuN–neuronal nuclei) was evaluated through double-immunofluorescence staining in sham and ACA animals at 24 hours after the injury (n=1 per group).

#### Experiment 2 (Short-term outcome)

The treatment effects of PAR2 inhibition on ACA outcomes were examined. Selective PAR2 inhibitor (FSLLRY-NH2; 50 μg/rat; Tocris Bioscience, Minneapolis, Minnesota, USA) was intranasally administered at 1 hour postresuscitation. Short-term neurological function was assessed through neurological deficit score (NDS) (24-hour, 48-hour, and 72-hour postresuscitation), and neurocognition was evaluated using T-maze test (7 days) after ACA. The effect of FSLLRY-NH2 on hippocampal neuron degeneration was evaluated through Fluoro-Jade C (FJC) staining 7 days after ACA.

### Intrasanal Drug Administration

One hour after ACA, FSLLRY-NH2 was diluted in 20% ethanol and administered intranasally as previously described (24). Briefly, the animals were placed in supine position under 2% isoflurane anesthesia. A total volume of 30 microliters (μL) of vehicle (20% ethanol) or FSLLRY-NH2 (50 μg/rat) in 20% ethanol was administered to the left and right nares, alternately administering 5 μL in one naris every 2 minutes for a period of 10 minutes.

### Assessment of Neurological Function

Neurological functions were assessed by a blinded investigator. Consciousness, respiration, corneal reflex, auditory reflex, motor function, and behavior were evaluated through NDS at 24, 48, and 72 hours after ACA. Higher scores indicated worse performance. The total test score ranged between 0 (normal)
and 500 (coma) (10). Cognitive deficits were evaluated using T-maze spontaneous alternation test 7 days after ACA. For this test, the percentage of spontaneous alternation (number of turns in each goal arm) was recorded, and the results were expressed as percent with respect to 50% reference (15,22).

**Histological Analysis**

Briefly, the rats underwent transcardiac perfusion with 100 mL of chilled phosphate-buffered saline (PBS; 0.01 M; pH 7.4), followed by 100 mL of 10% formalin under deep anesthesia. The brains were quickly removed, fixed in 10% formalin at 4 °C for 24 hours, and then dehydrated in 30% sucrose for another 72 hours. After being embedded into OCT (Scigen Scientific Gardena, California, USA), the 10 micrometer coronal brain sections were obtained at 3.8 millimeter (mm) posterior to the bregma on a cryostat (CM3050S; Leica Microsystems, Bannockburn, Ill, Germany).

Double-immunofluorescence staining was performed as previously described (45). Briefly, the slices were washed in 0.01 M of PBS (3 × 5 minutes) and blocked with 5% donkey serum at room temperature for 1 hour. Then, the slices were incubated overnight at 4 °C with the following primary antibodies: anti-PAR2 (1:200), anti-Iba1 (1:200), anti-GFAP (1:200), and anti-NeuN (1:200) (all from Abcam, Cambridge, Massachusetts, USA). The sections were incubated with appropriate fluorescence-conjugated secondary antibodies (1:100, Jackson Immuno Research, West Grove, Pennsylvania, USA) at room temperature for 1 hour the following day. The slides were then visualized and photographed under a fluorescence microscope (BZ-X800; Keyence Corporation, Itasca, Illinois, USA).

As previously described (24, 30), FJC Ready-to-Dilute Staining Kit (Biosensis, USA) was used for FJC staining based on the manufacturer’s instructions. ImageJ software (ImageJ 1.4, NIH, USA) was used to count the number of FJC-positive neurons. Data gathered were presented as the number of FJC-positive neurons expressed in per mm$^2$ in the fields.

**Western Blot Analysis**

Western blot analysis was performed as previously described (38,42,44). Briefly, the animals underwent transcardiac perfusion of 100 mL of ice-cold PBS (0.01 M; pH 7.4) under deep sedation before the brains were quickly removed. Brain samples were snap frozen in liquid nitrogen and stored at a temperature of −80°C until use. During sample preparation, tissues were homogenized in RIPA Lysis Buffer (Santa Cruz Biotechnology Inc., Texas, USA) and centrifuged at 14,000 g at 4°C for 30 minutes. Using detergent-compatible assay (DC protein assay; Bio-Rad Laboratories, California, USA), protein concentrations of the supernatants were measured. Then, equal amounts of protein (30 µg) were separated through SDS-PAGE gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked with 5% non-fat-blocking grade milk (Bio-Rad, Hercules, California, USA) and incubated overnight at 4°C with the following primary antibodies: anti-PAR2 (1:500) and anti-β actin (1:2000) (all from Santa Cruz Biotechnology, Dallas, Texas, USA). The membranes were incubated with the appropriate secondary antibody (1:2000, Santa Cruz, Dallas, Texas, USA) at room temperature for 2 hours the following day. The bands were visualized with ECL Plus chemiluminescence reagent kit (Amersham Bioscience, Pennsylvania, USA). ImageJ software (Image J 1.4, NIH, USA) was used to quantify the densities of the immunoblots. β-actin was used as internal control.

**Statistical Analysis**

All data were presented as mean ± standard deviation (mean ± SD) and were analyzed using GraphPad Prism 7 (GraphPad Software, San Diego, California, USA). One-way ANOVA followed by Tukey’s post hoc test was used for comparison among multiple groups. A p value <0.05 was considered statistically significant.

## RESULTS

### Mortality

No mortality was observed in the sham group. In the ACA group (n=33), ROSC was achieved in 26 rats (78.8%). Only the resuscitated rats in the ACA group (n=26) were further included for our experiments. Post-ROSC mortality was 0% (n=0). Moreover, no significant difference in the mortality rates among the ACA groups was observed (p=0.7075).
DISCUSSION

In this study, we focused on the potential neuroprotective effect of PAR2 inhibition using an ACA rat model. Our findings were as follows: 1) PAR2 is expressed in the brain both in rats subjected to sham operation and ACA; 2) PAR2 expression significantly increased in the brain after ACA-induced GCI; 3) ACA resulted in significantly increased neuron degeneration in the hippocampal CA1 region and short-term neuronal dysfunction; 4) Inhibition of PAR2 with its selective inhibitor (FSLLRY-NH2) significantly reduced hippocampal neuron degeneration and improved short-term neurocognitive decline caused by ACA.

As outlined in the introduction section, neurocognitive impairment is a well-known consequence of CA. This is due to the vulnerability of the hippocampus, particularly the pyramidal neurons in the hippocampal CA1 region to transient ischemia such as CA-induced GCI (8,13,39). Consequently, substantial loss of pyramidal neurons in the hippocampal CA1 region but not in the CA2 or CA3 region and dentate gyrus was demonstrated after GCI (13,39). Consistent with the well-known role of the hippocampus in memory formation, cognition, and spatial learning (2,6,24), earlier clinical studies showed that cognitive decline may last up to 3 years after CA-induced GCI and obviously decreases the patients’ quality of life (34). Therefore, strategies targeting improvement of neurological dysfunction after CA are mandatory.

PAR2 belongs to the PAR family, which is a G-protein-coupled receptor family that is activated by cleavage of a section of the amino terminus by serine proteinases (33). PAR2 is widely expressed in the brain, and it is preferentially activated by trypsin and mast cell tryptase, whereas PAR1, PAR3, and PAR4 are preferentially activated by thrombin (31). The activation of PAR2 has been implicated in neuroinflammation and neurodegeneration (4,9,12). The activation of microglial and astrocytic PAR2 was demonstrated to result in the release of proinflammatory cytokines IL-6 and TNF-α in earlier in vitro studies (40,41). In addition, induced PAR2 expression...
Figure 3: Inhibition of PAR2 with FSLRRY-NH2 improved short-term neurological deficits after ACA. Effect of FSLRRY-NH2 on neurological deficit score (NDS) was assessed at 24 (A), 48 (B) and 72 (C) hours after ACA. ACA was associated with significantly worse neurologic functions compared to the shams at all time points. Inhibition of PAR2 with FSLRRY-NH2 at a dose of 50 µg improved NDS at 24, 48 and 72 hours after ACA compared to the vehicle treated ACA rats. (Data are expressed as mean ± SD. n= 4-6/group. **p<0.001 compared to Sham, *p<0.05 compared to Sham, #p<0.05 compared to ACA + vehicle; ANOVA, Tukey).

Figure 2: Cellular co-localization of PAR2 in neurons, astrocytes and microglia. Representative double-immunofluorescence staining microphotography at 24 hours following ACA showed that PAR2 (green) co-localized with neuronal, astrocytic and microglial markers NeuN (A), astrocytes (GFAP) (B), and microglia (iba-1) (C) (all red). Nuclei of the cells are stained with DAPI (A,B,C) (blue). The location of staining was indicated as small red box in coronal brain slice. (Scale bar= 50 μm, n= 1/group).
Ocak U. et al: Role of FSLLRY-NH2 on Neurological Outcome

in response to alpha-synuclein, which is known to trigger neurodegeneration, was reported in the brains of patients with Parkinson’s disease (12). Similarly, enhanced expression of PAR2 was found in the brain in patients with Alzheimer’s disease (1) as well as multiple sclerosis (28).

Although data regarding the alterations in PAR2 expression after brain ischemia remain controversial, several previous studies demonstrated increased protein levels of PAR2 in severely ischemic brain (25,36). Moreover, PAR2 was shown to be highly expressed in the hippocampus, and its activation negatively affected learning functions and cognition (19,35). Consistent with previous results, we showed in this study that PAR2 is expressed in the resident cells of the brain including microglia, astrocytes, and neurons in the animals subjected to asphyxia-induced CA. We also showed that the expression of PAR2 significantly increased in the brain after CA by using Western blot analysis. In addition, increased neuron degeneration that was observed in the hippocampal CA1 slices obtained from ACA animals 7 days after the injury was effectively reduced by administering a selective inhibitor, FSLLRY-NH2, of PAR2 in our study. Consistently, the animals treated with FSLLRY-NH2 exhibited better performance in neurological tests as defined by lower NDS and also improved neurocognitive performance in T-maze test in the current study.

This study has several limitations. First, the contribution of PAR2 to neuronal apoptosis (32) as well as blood–brain damage (43) was reported in earlier studies, in addition to its proinflammatory effects (29). We did not investigate the detailed mechanisms underlying the neuroprotection provided by PAR2 inhibitor in the setting of GCI after ACA. Second, we have not evaluated long-term effect of PAR2 inhibition against neurological impairments after ACA. Therefore, our future studies will further address these issues.

CONCLUSION

In summary, inhibition of PAR2 with FSLLRY-NH2 improved short-term neurological impairments and attenuated neuronal degeneration in the hippocampal CA1 region in an ACA rat model. Our findings suggest that targeting brain PAR2 may be a novel therapeutic strategy in managing neurocognitive decline in CA survivors.
ACKNOWLEDGEMENTS

This work was funded by LLU School of Medicine-Department of Neurosurgery funding (IACUC Record Number: 8180029). Preparation for publication of this article is partly supported by Turkish Neurosurgical Society.

The affiliations of authors:
*Bursa City Hospital, Department of Emergency Medicine, Bursa, Turkey

**Loma Linda University School of Medicine, Department of Neurosurgery, Loma Linda, California, USA

***Loma Linda University School of Medicine, Department of Anesthesiology and Neurology, Loma Linda, California, USA

REFERENCES


